Shots:

• Shoreline is eligible to receive ~$2.3B including upfront- development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in Shoreline’s recent Series A financing
• The collaboration will utilize Shoreline’s iPSC differentiation and genetic reprogramming with Kite’s cell therapy to develop novel allogeneic therapies for hematologic malignancies
• Initially- the collaboration will focus on CAR NK targets- with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post deal execution

| Ref: Gilead | Image: Glassdoor